PMID- 27416072
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20181202
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 63
IP  - 11
DP  - 2016 Nov
TI  - Zoledronate as effective treatment for minimal trauma fractures in a child with 
      STAT3 deficiency and osteonecrosis of the hip.
PG  - 2054-7
LID - 10.1002/pbc.26119 [doi]
AB  - Signal transducer and activator of transcription 3 (STAT3) deficiency is a 
      primary immunodeficiency characterized by eczema, complicated recurrent 
      infections, elevated serum immunoglobulin E (IgE), osteopenia, and minimal trauma 
      fractures. Zoledronic acid (ZA) is a long-acting bisphosphonate that has been 
      successfully used in children with secondary osteoporosis and osteogenesis 
      imperfecta. We describe the case of a 7-year-old male with STAT3 deficiency and 
      minimal trauma fractures, who also developed osteonecrosis of the hip. He 
      responded well to intravenous ZA every 6 months for 18 months. Three years later, 
      he walks independently and unaided, and has not suffered any other fractures. 
      Although more studies are needed, ZA might help reduce minimal trauma fractures 
      in patients with STAT3 deficiency.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Staines Boone, Aide Tamara
AU  - Staines Boone AT
AD  - Clinical Immunology Department, Hospital de Especialidades, Mexican Social 
      Security Institute (IMSS), Monterrey, Nuevo Leon, Mexico. 
      tamarastaines@gmail.com.
FAU - Alcantara-Montiel, Julio Cesar
AU  - Alcantara-Montiel JC
AD  - Department of Molecular Biomedicine, Center for Research and Advanced Studies 
      (CINVESTAV), National Polytechnic Institute (IPN), Mexico City, Mexico.
FAU - Sanchez-Sanchez, Luz Maria
AU  - Sanchez-Sanchez LM
AD  - Department of Pediatrics, Hospital de Especialidades, Mexican Social Security 
      Institute (IMSS), Monterrey, Nuevo Leon, Mexico.
FAU - Arce-Cano, Marina
AU  - Arce-Cano M
AD  - Department of Pediatrics, Hospital de Especialidades, Mexican Social Security 
      Institute (IMSS), Monterrey, Nuevo Leon, Mexico.
FAU - Garcia-Campos, Jorge
AU  - Garcia-Campos J
AD  - Department of Infectious Diseases, Hospital de Especialidades, Mexican Social 
      Security Institute (IMSS), Monterrey, Nuevo Leon, Mexico.
FAU - Lugo Reyes, Saul Oswaldo
AU  - Lugo Reyes SO
AD  - Immunodeficiencies Research Unit, National Institute of Pediatrics (INP), Mexico 
      City, Mexico.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160714
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Imidazoles)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Bone Density Conservation Agents/*therapeutic use
MH  - Child
MH  - Diphosphonates/*therapeutic use
MH  - Fractures, Bone/*drug therapy/etiology
MH  - Hip/*pathology
MH  - Humans
MH  - Imidazoles/*therapeutic use
MH  - Male
MH  - Osteonecrosis/*drug therapy
MH  - STAT3 Transcription Factor/*deficiency
MH  - Zoledronic Acid
OTO - NOTNLM
OT  - STAT3 deficiency
OT  - arthroplasty
OT  - avascular necrosis of the hip
OT  - bisphosphonate
OT  - hyper-IgE syndrome
OT  - job syndrome
OT  - osteonecrosis of the femoral head
OT  - osteopenia
OT  - primary immunodeficiency
OT  - zoledronic acid
EDAT- 2016/07/15 06:00
MHDA- 2017/06/18 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/03/14 00:00 [received]
PHST- 2016/05/17 00:00 [revised]
PHST- 2016/06/05 00:00 [accepted]
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
AID - 10.1002/pbc.26119 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2016 Nov;63(11):2054-7. doi: 10.1002/pbc.26119. Epub 2016 
      Jul 14.